Clinical trial

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer

NCT05489731

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-09-21

PhasePHASE1

Study timeline

Study start (actual)2022-09-21Date precision: day

Registry last updated2023-06-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Non-small Cell Lung Cancerunresolved

Interventions

VIC-1911DRUG

Osimertinib Mesylate TabletsDRUG

Sponsors & collaborators

Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05489731 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.